Amedisys, Inc. to Post Q1 2024 Earnings of $1.31 Per Share, Zacks Research Forecasts (NASDAQ:AMED)

Amedisys, Inc. (NASDAQ:AMEDGet Rating) – Analysts at Zacks Research cut their Q1 2024 earnings per share (EPS) estimates for Amedisys in a research note issued on Wednesday, January 4th. Zacks Research analyst U. Biswas now forecasts that the health services provider will post earnings of $1.31 per share for the quarter, down from their prior forecast of $1.32. The consensus estimate for Amedisys’ current full-year earnings is $4.84 per share. Zacks Research also issued estimates for Amedisys’ Q4 2024 earnings at $1.30 EPS and FY2024 earnings at $5.30 EPS.

AMED has been the topic of a number of other research reports. SVB Leerink reduced their target price on Amedisys from $96.00 to $85.00 and set a “market perform” rating on the stock in a report on Thursday. Jefferies Financial Group reiterated a “buy” rating and set a $150.00 price target on shares of Amedisys in a report on Wednesday, November 2nd. StockNews.com downgraded Amedisys from a “buy” rating to a “hold” rating in a report on Monday, January 2nd. Benchmark reduced their target price on Amedisys from $165.00 to $135.00 and set a “buy” rating for the company in a research note on Monday, October 3rd. Finally, Royal Bank of Canada cut their price target on Amedisys from $165.00 to $139.00 and set an “outperform” rating for the company in a research note on Monday, October 31st. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Amedisys has a consensus rating of “Hold” and an average target price of $135.44.

Amedisys Price Performance

Amedisys stock opened at $82.60 on Monday. Amedisys has a 12 month low of $79.48 and a 12 month high of $179.91. The stock’s 50 day moving average is $86.63 and its 200-day moving average is $104.23. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $2.68 billion, a price-to-earnings ratio of 22.26, a PEG ratio of 1.96 and a beta of 0.96.

Amedisys (NASDAQ:AMEDGet Rating) last released its earnings results on Wednesday, October 26th. The health services provider reported $1.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.24 by ($0.09). Amedisys had a return on equity of 16.00% and a net margin of 5.45%. The company had revenue of $557.99 million for the quarter, compared to the consensus estimate of $579.30 million. During the same quarter in the previous year, the company posted $1.53 EPS. The business’s revenue was up .8% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. purchased a new position in Amedisys in the 3rd quarter worth approximately $103,633,000. Impax Asset Management Group plc acquired a new stake in Amedisys in the third quarter worth $48,461,000. Mackenzie Financial Corp increased its position in Amedisys by 67.7% in the first quarter. Mackenzie Financial Corp now owns 956,780 shares of the health services provider’s stock worth $164,844,000 after buying an additional 386,411 shares during the period. Ensign Peak Advisors Inc grew its stake in shares of Amedisys by 166.3% in the second quarter. Ensign Peak Advisors Inc now owns 572,598 shares of the health services provider’s stock worth $60,190,000 after purchasing an additional 357,598 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Amedisys by 21.8% during the second quarter. JPMorgan Chase & Co. now owns 1,685,940 shares of the health services provider’s stock valued at $177,225,000 after buying an additional 301,899 shares in the last quarter. Institutional investors and hedge funds own 96.17% of the company’s stock.

Amedisys Company Profile

(Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Read More

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.